Literature DB >> 14522889

Lack of BRAF mutations in uveal melanoma.

Donata Rimoldi1, Suzanne Salvi, Danielle Liénard, Ferdy J Lejeune, Daniel Speiser, Leonidas Zografos, Jean-Charles Cerottini.   

Abstract

RAF proteins are serine/threonine kinases that mediate cellular responses to growth signals by activating the mitogen-activated protein kinase pathway. Mutations in the BRAF gene causing a V599E amino acid substitution that enhance the kinase activity have been described in >60% of cutaneous melanomas and premalignant melanocytic lesions. We have investigated the frequency of BRAF mutations at the expression level in melanomas of the uveal tract. None of the 30 metastases and 10 primary uveal melanomas tested expressed the V599E mutation. In contrast, this mutation was expressed by 65% of cutaneous melanoma samples, confirming previous results. In addition, a double mutation resulting in V599K substitution was detected in two suspect ocular metastases of cutaneous melanoma. Analysis of exon 11, the second common site of BRAF mutations, revealed only wild-type sequences in uveal melanomas. Analysis of tumor lysates showed the presence of phosphorylated mitogen-activated protein kinase, kinase, and mitogen-activated protein kinase in 50% of uveal and 100% of cutaneous melanoma metastases. Taken together, these results suggest that although the common BRAF mutations found in cutaneous melanoma do not play a role in tumorigenesis of uveal tract melanocytes, activation of the RAF/mitogen-activated protein kinase pathway may nevertheless play an important role in uveal melanoma.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14522889

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  53 in total

Review 1.  Melanoma: from mutations to medicine.

Authors:  Hensin Tsao; Lynda Chin; Levi A Garraway; David E Fisher
Journal:  Genes Dev       Date:  2012-06-01       Impact factor: 11.361

Review 2.  Driver mutations in melanoma: lessons learned from bench-to-bedside studies.

Authors:  Janice M Mehnert; Harriet M Kluger
Journal:  Curr Oncol Rep       Date:  2012-10       Impact factor: 5.075

3.  Usefulness of nivolumab plus ipilimumab immunotherapy for metastatic uveal melanoma.

Authors:  Brittany Miles; John Moth; James Mackey
Journal:  Proc (Bayl Univ Med Cent)       Date:  2020-10-19

Review 4.  Latest developments in the biology and management of uveal melanoma.

Authors:  Sapna P Patel
Journal:  Curr Oncol Rep       Date:  2013-12       Impact factor: 5.075

5.  Effects of Oncogenic Gαq and Gα11 Inhibition by FR900359 in Uveal Melanoma.

Authors:  Dominic Lapadula; Eduardo Farias; Clinita E Randolph; Timothy J Purwin; Dougan McGrath; Thomas H Charpentier; Lihong Zhang; Shihua Wu; Mizue Terai; Takami Sato; Gregory G Tall; Naiming Zhou; Philip B Wedegaertner; Andrew E Aplin; Julio Aguirre-Ghiso; Jeffrey L Benovic
Journal:  Mol Cancer Res       Date:  2018-12-19       Impact factor: 5.852

Review 6.  Biology and treatment of BRAF mutant metastatic melanoma.

Authors:  Benjamin Y Kong; Matteo S Carlino; Alexander M Menzies
Journal:  Melanoma Manag       Date:  2016-02-12

Review 7.  Molecular pathology of uveal melanoma.

Authors:  S E Coupland; S L Lake; M Zeschnigk; B E Damato
Journal:  Eye (Lond)       Date:  2012-12-07       Impact factor: 3.775

Review 8.  Chemoprevention of melanoma.

Authors:  Marie-France Demierre; Glenn Merlino
Journal:  Curr Oncol Rep       Date:  2004-09       Impact factor: 5.075

9.  Establishment and Characterization of Orthotopic Mouse Models for Human Uveal Melanoma Hepatic Colonization.

Authors:  Shinji Ozaki; Raja Vuyyuru; Ken Kageyama; Mizue Terai; Masahiro Ohara; Hanyin Cheng; Tim Manser; Michael J Mastrangelo; Andrew E Aplin; Takami Sato
Journal:  Am J Pathol       Date:  2015-11-25       Impact factor: 4.307

10.  Episodic Src activation in uveal melanoma revealed by kinase activity profiling.

Authors:  W Maat; M el Filali; A Dirks-Mulder; G P M Luyten; N A Gruis; L Desjardins; P Boender; M J Jager; P A van der Velden
Journal:  Br J Cancer       Date:  2009-06-30       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.